生物医药

抗病毒、抗肿瘤药物的发现及作用机制的研究

1. Li Y#, Zhu X#, Zhang J, Lin Y, You X, Chen M, Wang Y, Zhu N*, Si S*. Identification of a Compound That Inhibits the Growth of Gram-Negative Bacteria by Blocking BamA-BamD Interaction. Front Microbiol. 2020，Jun 19;11:1252.
2. Yunyu Chen1#, Jing Zhang1#, Dongsheng Li1, Jiandong Jiang1, Yanchang Wang2, Shuyi Si1.Identification of a Novel Polo-like Kinase 1 Inhibitor that Specifically Blocks Polo-Box Domain-Mediated Protein-Protein Interactions. Oncotarget. 2017, 8(1):1234-1246.
3. Han X#, Zhang J#, Guo L, Cao R, Li Y, Li N, Ma Q, Wu J*, Wang Y*, Si S*. A series of beta-carboline derivatives inhibit the kinase activity of PLKs. PLoS one, 7(10):e46546. Epub 2012 Oct 3.
4.Yuan Lina,1, Yan Lia,1, Yuanjun Zhua,c, Jing Zhanga, Yongzhen Lia, Xiao Liua,Chunling Xiaoa, Bin Honga, Jiandong Jianga,2, Yanchang Wangb,2, Shuyi Sia,2. Identification of anti-tuberculosis agents that target ribosome subunit interaction using yeast two-hybrid system. Proc Natl Acad Sci U S A, 2012 Oct 23;109(43):17412-17417.
5. Jing Zhang#, Yan Li#, Liang Guo, Rihui Cao, Pei Zhao, Wei Jiang, Qin Ma, Hong Yi, Zhuorong Li, Jiandong Jiang, Jialin Wu*, Yanchang Wang*, Shuyi Si*. DH166, a beta-carboline derivative, inhibits the kinase activity of PLK1. Cancer Biol Ther,2009,8(24): 2374-2383.

1. 司书毅，赵午莉，陈明华，常珊珊，张聪慧，王俊霞，邵荣光，余利岩，肖同美，李妍，甄心，姜威，许艳妮，张晶，刘超; 多硫代二酮哌嗪类化合物Secoemerstrin C的制备方法及其用途, 2021-02-23, 中国, ZL201911160563.6
2. 程景才，司书毅，张晶，许艳妮，姜新海，徐扬，杨晨，李依宁，王伟志，韩江雪，异硫氰酸酯类化合物的用途，202010093605.5，申请日：2020.2.14
3. 司书毅，陈云雨，张晶，王彦昶，蒋建东，李妍，李东升；化合物T521或其结构类似物制备抗肿瘤药物的应用，2018-2-2，中国，ZL201510370118.8
4. 司书毅，张晶，陈云雨，王彦昶，蒋建东，朱宁屿，李妍，陈明华，刘超；化合物F083-0063及其抗肿瘤应用，2019-2-5，中国，ZL201710128766.1
5. 司书毅，高娜娜，姜威，蒋建东，李妍，李东升，李永臻，张晶，朱宁屿，王智敏；取代的N-（1’，3’-杂唑-4’-基）-4-苯甲酰基六氢吡啶类化合物及其用途，2017-1-25，中国，ZL201210253347.8
6. 司书毅，高娜娜，姜威，蒋建东，李妍，李东升，李永臻，张晶，朱宁屿，王智敏；取代的苯并-1,3-杂唑类化合物、及制备方法及用途，2017-1-11，中国，ZL201310505300.0

技术咨询